Importantly, this study validates that XKY alters the gut microbiota, reduces LCA and DCA levels to promote hepatic BA synthesis by inhibiting the FXR-FGF15 signaling pathway; and regulates AA metabolism (arginine biosynthesis; alanine, aspartate and glutamate metabolism; phenylalanine, tyrosine and tryptophan biosynthesis; and tryptophan metabolism), which play an important role in the pathological process of metabolic diseases. Here, NR1H4 is linked to metabolic disease.